“Sloppy” Searle Studies Described By FDA At Kennedy Hearing; Rauscher “Outraged”
In Brief: Override Failure Would Leave Cancer Program With No Money or New Projects Of Any Kind
NCI Budget for FY 1977 Would Halt New Research
Congressman Obey Attacks NCI for Not Supporting Basic Research
Nutrition RFPs Will Really Be Grants, Gori Says
Cyclamate Committee Finds No Proof Of Carcinogenicity
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Trump targets HHS in $810M appropriations clawback
- Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?









